Higher cure rates in acute leukemia: now more probable with increasingly effective induction therapy

Traditional therapy of acute myelogenous leukemia has not cured more than 10% of patients and, of acute lymphoblastic leukemia not more than 30% of adults. In part, this is due to the lack of agents effective enough to induce remissions of such quality that cure is possible. The introduction of mito...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical & laboratory research 1992-06, Vol.21 (4), p.273-277
Main Authors: Arlin, Z A, Ahmed, T, Mittelman, A, Cook, P, Puccio, C A, Helson, L, Chun, H G
Format: Article
Language:English
Subjects:
Acute Disease
Adult
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bone Marrow Transplantation
Cell Survival - drug effects
Child
Clinical Protocols
Combined Modality Therapy
Humans
Leukemia - drug therapy
Leukemia - mortality
Leukemia - surgery
Middle Aged
Neoplastic Stem Cells - drug effects
Remission Induction
Survival Rate
Transplantation, Autologous
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Traditional therapy of acute myelogenous leukemia has not cured more than 10% of patients and, of acute lymphoblastic leukemia not more than 30% of adults. In part, this is due to the lack of agents effective enough to induce remissions of such quality that cure is possible. The introduction of mitoxantrone and its use in high dose with high-dose cytarabine for induction therapy, raises the possibility of an increased cure rate of acute myelogenous leukemia and acute lymphoblastic leukemia.
ISSN:0940-5437
1434-4467
DOI:10.1007/BF02591660